Contrive Datum Insights recent study on the “Global Diabetic Macular Edema Drugs Market” (By Drug Type (Anti-Vascular Endothelial Growth Factor (VEGF), Corticosteroids); By Treatment Method (Laser Photocoagulation Therapy, Intravitreal Implants); By End User (Hospitals, Clinics, Others), 2019 – 2026 offers updated industry insights, growth perspective and dynamics about the competitiveness in the market.
Increase in patients suffering from diabetes and towards macular edema across the globe is enabling a need for diabetic macular edema drugs market. In the year 2011, more than 346 million were affected by diabetes and the trend is continuing with a faster rate, wherein, double the number of affected diabetes patient is expected to attain till 2030. Following the trends of increasing diabetic patients, global diabetic macular edema drugs market is expected to grow at a CAGR of XX% over the forecasted period (2019 – 2026).
Increasing Incidences of diabetic retinopathy patients across the globe is leveraging the demand for diabetic macular edema drugs market.
Diabetic macular edema occurs primarily among the diabetes mellitus patients. The disease is caused when fluid from damaged blood vessels in retina leaks or accumulates down to the macula, i.e. towards the back portion of eye and thereby, leading in thickening and swelling of retina. As a result, patient suffering from disease would lead to have distorted vision. The most common cause of diabetic macular edema is diabetic retinopathy, which majorly affects both the eyes in the course of time. Furthermore, as per the experts it is observed that out of 7.7 million American diabetic retinopathy patients, around 750000 have diabetic macular edema. In addition, based on a recent study it is also observed that African American population have higher incidences towards diabetic macular edema. However, macular edema symptoms and disease can also happen after any type of eye surgery. Thus, patients that have undergone, cataract, glaucoma or retinal disease surgeries has high chances of developing the disease. Thus, with the growth in macular edema disease among diabetic patients is likely to surge the market.
Advancement in intravitreal implantation agents for efficient visual gain is leading to the development of global diabetic macular edema drugs market.
The rising consequences of diabetic macular edema among the diabetic retinopathy patients have led to the need for treatment therapies. Laser photocoagulation therapy is the standard treatment type for the disease. The therapy is categorized based on the two types, which are focal and grid. The focal laser treatment is to reduce the leakage of microaneurysms and grid laser treatment is used in the diffuse leakage area of thicken retina. Thus, laser treatment is considered as a standard therapy since a long time, as it improves the vison loss symptoms. However, with the rapid development in medical science and technology, intravitreal administration of anti angiogenic agents and anti-inflammatory along with laser therapy is gaining prominence. These agents are classified as corticosteroids and anti VEGF. In addition based on the treatment type, intravitreal implantation offers better and efficient visual gains as compared to laser interventions.
Global Diabetic Macular Edema Drugs Market, Revenue (USD Million), 2019 – 2026
The competitive landscape of the global diabetic macular edema drugs market consists of several global and regional players. Some of the players in the market include. Alimera Sciences, Allergan, Bausch & Lomb, Bayer AG, F. Hoffmann-La Roche Ltd, Kubota Pharmaceutical Holdings Co. Ltd, Novartis AG, Oculis, Pfizer Inc., Regeneron Pharmaceuticals Inc. amongst others.
Diabetic Macular Edema Drugs Type, Overview, 2019 – 2026 (USD Million)
- Anti-Vascular Endothelial Growth Factor (VEGF)
Diabetic Macular Edema Drugs Treatment Method, Overview, 2019 – 2026 (USD Million)
- Laser Photocoagulation Therapy
- Intravitreal Implants
Diabetic Macular Edema Drugs End User, Overview, 2019 – 2026 (USD Million)